Dova Pharmaceuticals Inc.
CIK 0001685071
Revenue (TTM)
$13.82M
−3.0% YoY
Q3 Nov 2019
Net Income (TTM)
−$74.25M
+1.0% YoY
Q3 Nov 2019
EPS Diluted (TTM)
—
Q3 Nov 2019
Gross Margin
—
Q3 Nov 2019
Operating Margin
-530.2%
Q3 Nov 2019
Net Margin
-537.3%
Q3 Nov 2019
Free Cash Flow (TTM)
−$25.41M
Q3 Nov 2019
Cash
$68.45M
Q3 Nov 2019
Total Debt
$30.84M
Q3 Nov 2019
Shares Outstanding
28.85M sh
Q3 Nov 2019
Revenue & Net Income
Margins
Cash Flow
Revenue Growth (YoY)
No data available for this metric.